4.6 Article

Urinary Proteomics Profiles Are Useful for Detection of Cancer Biomarkers and Changes Induced by Therapeutic Procedures

期刊

MOLECULES
卷 24, 期 4, 页码 -

出版社

MDPI
DOI: 10.3390/molecules24040794

关键词

urine; thyroid cancer; squamous cell cancer of head and neck; BNCT; boron; proteomics; LC-MS; MudPIT

资金

  1. Italian CNR FLAGSHIPs Project - MIUR InterOmics
  2. AMANDA project - CNR-Lombardy Agreement
  3. European Commission [QLK3-CT-1999-01067, 005045]
  4. Fondazione Umberto Veronesi Fellowship

向作者/读者索取更多资源

Boron neutron capture therapy (BNCT) is a binary cancer treatment modality where two different agents (B-10 and thermal neutrons) have to be present to produce an effect. A dedicated trial design is necessary for early clinical trials. The concentration of B-10 in tissues is an accepted surrogate to predict BNCT effects on tissues. Tissue, blood, and urines were sampled after infusion of two different boron carriers, namely BSH and BPA in the frame of the European Organisation for Research and Treatment of Cancer (EORTC) trial 11001. In this study, urine samples were used to identify protein profiles prior and after drug infusion during surgery. Here, an approach that is based on the mass spectrometry (MS)-based proteomic analysis of urine samples from head and neck squamous cell carcinoma (HNSCC) and thyroid cancer patients is presented. This method allowed the identification of several inflammation- and cancer-related proteins, which could serve as tumor biomarkers. In addition, changes in the urinary proteome during and after therapeutic interventions were detected. In particular, a reduction of three proteins that were involved in inflammation has been observed: Galectin-3 Binding Protein, CD44, and osteopontin. The present work represents a proof of principle to follow proteasome changes during complex treatments based on urine samples.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据